REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

21 نوفمبر 2024 09:19:05 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

20 نوفمبر 2024 08:58:38 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 نوفمبر 2024 09:06:22 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 نوفمبر 2024 08:45:40 بحسب NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 نوفمبر 2024 08:45:06 بحسب NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

14 نوفمبر 2024 23:59:51 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

14 نوفمبر 2024 14:47:28 بحسب NetDania Notify

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

13 نوفمبر 2024 06:00:25 بحسب Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 نوفمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

06 نوفمبر 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Regeneron Reports Third Quarter 2024 Financial and Operating Results

31 أكتوبر 2024 05:30:01 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

24 أكتوبر 2024 07:00:04 بحسب Nasdaq GlobeNewswire

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

18 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

27 سبتمبر 2024 08:35:08 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

27 سبتمبر 2024 06:00:04 بحسب Nasdaq GlobeNewswire

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

26 سبتمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

20 سبتمبر 2024 06:45:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

13 سبتمبر 2024 11:15:28 بحسب Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

11 سبتمبر 2024 06:00:46 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

11 سبتمبر 2024 00:04:00 بحسب Nasdaq GlobeNewswire